B Romanowski

Summary

Publications

  1. ncbi Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics
    Ameeta E Singh
    University of Alberta, Alberta, Canada
    Sex Transm Dis 32:95-100. 2005
  2. ncbi Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics
    Barbara Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 30:33-8. 2003
  3. ncbi Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study
    Barbara Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 30:226-31. 2003
  4. pmc Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study
    Barbara Romanowski
    University of Alberta, Edmonton, AB, Canada
    Hum Vaccin 7:1374-86. 2011
  5. ncbi Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines
    Barbara Romanowski
    University of Alberta, Edmonton, AB, Canada
    Hum Vaccin 7:161-9. 2011
  6. doi Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
    B Romanowski
    University of Alberta, 1000 8215 112 Street, Edmonton, AB, Canada, T6G 2C8
    Lancet 374:1975-85. 2009
  7. doi Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada
    Barbara Romanowski
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 36:165-9. 2009
  8. ncbi In search of optimal genital herpes management and standard of care (INSIGHTS): doctors' and patients' perceptions of genital herpes
    B Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Infect 84:51-6. 2008
  9. ncbi Serologic response to treatment of infectious syphilis
    B Romanowski
    STD Control, Alberta Health, Edmonton, Canada
    Ann Intern Med 114:1005-9. 1991
  10. ncbi Interferon treatment of multiple pulmonary malignancies associated with papilloma virus
    S Aaron
    University of Alberta, Edmonton
    Can Respir J 11:443-6. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics
    Ameeta E Singh
    University of Alberta, Alberta, Canada
    Sex Transm Dis 32:95-100. 2005
    ..The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics...
  2. ncbi Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics
    Barbara Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 30:33-8. 2003
    ..Hepatitis C virus (HCV) is a major global problem, transmitted primarily by percutaneous exposure to contaminated blood...
  3. ncbi Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study
    Barbara Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 30:226-31. 2003
    ..Valacyclovir is effective for suppressive and episodic treatment of recurrent genital herpes. Few data on patients' treatment strategy preferences are available...
  4. pmc Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study
    Barbara Romanowski
    University of Alberta, Edmonton, AB, Canada
    Hum Vaccin 7:1374-86. 2011
    ..These results indicate that the HPV-16/18 vaccine on a 2D M0,6 schedule is immunogenic and generally well tolerated in girls 9-14 y and that the 2D schedule is likely adequate for younger females...
  5. ncbi Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines
    Barbara Romanowski
    University of Alberta, Edmonton, AB, Canada
    Hum Vaccin 7:161-9. 2011
    ..Cross-protection against non-vaccine types appears stronger with the bivalent vaccine. However, both vaccines may provide sufficient immunogenicity to confer long-term protection. Ongoing monitoring is essential...
  6. doi Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
    B Romanowski
    University of Alberta, 1000 8215 112 Street, Edmonton, AB, Canada, T6G 2C8
    Lancet 374:1975-85. 2009
    ..Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years...
  7. doi Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada
    Barbara Romanowski
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Dis 36:165-9. 2009
    ..To determine the seroprevalence of herpes simplex virus infection in a population of HIV-infected individuals in Canada...
  8. ncbi In search of optimal genital herpes management and standard of care (INSIGHTS): doctors' and patients' perceptions of genital herpes
    B Romanowski
    University of Alberta, Edmonton, Alberta, Canada
    Sex Transm Infect 84:51-6. 2008
    ..To compare and contrast attitudes and behaviours of family doctors and patients with regard to genital herpes and its management...
  9. ncbi Serologic response to treatment of infectious syphilis
    B Romanowski
    STD Control, Alberta Health, Edmonton, Canada
    Ann Intern Med 114:1005-9. 1991
    ..To evaluate the serologic response to treatment of patients with infectious syphilis...
  10. ncbi Interferon treatment of multiple pulmonary malignancies associated with papilloma virus
    S Aaron
    University of Alberta, Edmonton
    Can Respir J 11:443-6. 2004
    ..Over the following seven years no new ones have appeared. The finding of papilloma virus in malignancies should prompt consideration of antiviral therapy...
  11. ncbi First year serologic response to treatment for syphilis: a model for prediction of seroreversion
    M S Rose
    Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta, Canada
    Stat Med 16:2103-15. 1997
    ..We recommend development of an action line be developed based on these variables. Such a line would indicate the necessity for retreatment if the line plotted from the patient's first year response failed to fall below the action line...
  12. pmc BVBlue test for diagnosis of bacterial vaginosis
    Linda Myziuk
    University of Alberta, Edmonton, Alberta, Canada
    J Clin Microbiol 41:1925-8. 2003
    ..98 times more likely to have another episode of BV. BVBlue is a useful point-of-care diagnostic tool to provide a presumptive diagnosis of BV, especially in situations where microscopic capabilities are unavailable...
  13. pmc Gonorrhea treatment guidelines in Canada: 2004 update
    Janice Mann
    Public Health Agency of Canada, Ottawa, Ont
    CMAJ 171:1345-6. 2004
  14. doi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  15. ncbi Report of the 2003 pan-Canadian forum on cervical cancer prevention and control
    Gavin Stuart
    Faculty of Medicine, University of British Columbia, Vancouver BC
    J Obstet Gynaecol Can 26:1004-28. 2004
    ..To develop evidence-based consensus recommendations on the delivery of cervical cancer screening, human papillomavirus (HPV) education, HPV testing, and the optimal tool for cervical cytology within the Canadian health system...